Simon Barnett

I recently attended the Molecular Machine Learning (MoML) Conference sponsored by the MIT Jameel Clinic, an institute focused on cutting-edge machine learning (ML) techniques in the life sciences. Computational approaches to drug discovery and development were the centerpiece of the symposium.  Investor sentiment for ML-centric discovery biotechs has been turbulent recently, but researchers at MoML were widely and consistently enthusiastic.... Read More